The Use of Artificial Intelligence in Medical Devices and Drug Development
Spire Wealth Management Cuts Stake in Bristol-Myers Squibb (NYSE:BMY)
Spire Wealth Management reduced its position in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 43.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exch
Preview -- Barron's
Monday 1/30 Franklin Resources, GE HealthCare Technologies, and NXP Semiconductors report quarterly results. Tuesday 1/31 Advanced Micro Devices, Amgen, Caterpillar, Chubb, Edwards Lifesciences, El
Arvest Trust Co. N A Increases Position in Bristol-Myers Squibb (NYSE:BMY)
Arvest Trust Co. N A increased its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 54.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commiss
Private Portfolio Partners LLC Sells 241 Shares of Bristol-Myers Squibb (NYSE:BMY)
Private Portfolio Partners LLC lessened its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 0.6% during the third quarter, according to its most recent filing with the Securities and Exchan
Bristol Myers Squibb Co. Stock Falls Friday, Underperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Bristol Myers Squibb Co. (BMY) slid 0.74% to $72.45 Friday, on what proved to be an all-aro
The Power of Dual Immunotherapy
NORTHAMPTON, MA / ACCESSWIRE / January 27, 2023 / Originally published on Bristol Myers Squibb News & PerspectivesA decade ago, the evolution of immuno-oncology transformed the landscape of therapy fo
Bristol-Myers Squibb's Reblozyl Receives Positive Opinion From European Medicines Agency
07:53 AM EST, 01/27/2023 (MT Newswires) -- Bristol-Myers Squibb Company (BMY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval o
Bristol Myers Gets CHMP Backing for Sotyktu, Reblozyl >BMY
By Colin Kellaher Bristol Myers Squibb Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended initial approval of its psoriasis drug Sotyktu
Bristol-Myers Announces CHMP Opinion Recommending Approval for Reblozyl
Loading...
No Stock Yet